CEO Executive AssistantImmuno-oncology CEO time management across combination therapy programs is one of the most structurally complex challenges in biopharma leadership today. Unlike single-agent programs with a clean development path, combination therapy portfolios involve multiple simultaneous scientific questions, overlapping partnership obligations, competing trial designs, and a scientific advisory ecosystem that requires continuous, substantive engagement. A CEO running two or three combination programs across different mechanisms (PD-1/PD-L1 combinations, CAR-T combination strategies, bispecific antibody programs) faces a level of coordination complexity that no amount of scientific expertise alone can resolve.
The question is not whether an immuno-oncology CEO needs to be deeply engaged across their combination portfolio. They do. The question is how to structure that engagement so it generates strategic clarity rather than operational fragmentation.
The Core Time Management Problem in Combination IO
A single combination therapy program is already complex. It involves at minimum two mechanisms of action, one or more pharma collaborators if the combination includes a partner’s asset, an academic medical center (AMC) or cooperative group running the trial, a scientific advisory board with opinions about biomarker strategy, and a regulatory affairs team working through the novelty of the combination’s approval pathway.
Now multiply that across three or four programs simultaneously. The CEO of a mid-size immuno-oncology company in 2026 may be managing a PD-1 combination with a large pharma partner, a CAR-T combination study at one or two AMCs, a bispecific program with its own partnership structure, and preclinical combination work feeding the next generation of programs. Each of these demands a different kind of CEO engagement and involves a different external relationship ecosystem.
Without a deliberate time architecture, the result is a CEO who attends every relevant meeting, contributes to every decision, and is perpetually reactive. This pattern burns out the CEO, slows decision-making because everything waits for their availability, and signals to the organization that leadership does not trust its scientific and clinical teams.
Partnership Management: Time Allocation Across Multiple Pharma Collaborators
Combination therapy programs almost always involve at least one large pharma partner whose asset is part of the combination. Managing that relationship well is a material determinant of whether the combination program gets the internal resources and prioritization it needs within the partner organization.
What the CEO Owns in a Pharma Partnership
The CEO’s role in a pharma collaboration is to manage the executive relationship at the partner company, make strategic decisions when the partnership agreement creates ambiguity, and ensure the joint steering committee (JSC) structure is functioning effectively.
The CEO should have a direct relationship with the equivalent senior executive at the partner company (typically a CMO, CSO, or Head of Oncology) and should invest in that relationship through periodic direct contact, not just JSC meetings. A brief quarterly call or in-person meeting that operates outside the formal JSC structure is one of the highest-ROI time investments an IO CEO can make. When a difficult decision arises in the partnership, the quality of that personal relationship determines whether it is resolved collaboratively or escalates into a contractual dispute.
The CEO should not be attending JSC meetings for all programs simultaneously unless the company is very early stage and the CEO is also functioning as the Chief Scientific Officer. As programs mature and the JSC structures become routine, the CEO’s direct involvement in JSC operations should decrease, with the CMO or VP of Clinical Development managing the operational relationship.
Managing Multiple Partners Without Conflating Them
Each pharma partner has its own strategic priorities, internal culture, and tolerance for complexity. A CEO managing relationships with two or three different pharma partners needs to maintain clear mental separation between each partnership: what each partner cares about, what the current tension points are, and what each partner’s internal champion needs from the CEO relationship.
An executive assistant’s role here is material. Maintaining up-to-date relationship profiles for each partner organization, tracking outstanding commitments from both sides, and ensuring the CEO is briefed before every partner interaction prevents the kind of context confusion that damages relationships at high-stakes moments.
Scientific Advisory Board Engagement
A well-constituted scientific advisory board (SAB) in immuno-oncology provides genuine strategic value: access to the most current thinking about combination mechanisms, biomarker strategy, trial design, and competitive intelligence from within academic medicine. It also creates a significant time obligation.
Structuring SAB Engagement for Maximum Return
Most IO companies hold formal SAB meetings two or three times per year. The CEO should attend these meetings personally. The strategic value of an SAB is substantially diminished if the CEO receives a summary briefing rather than engaging directly with the advisors.
However, the CEO is not the person managing the SAB relationship administratively. Scheduling, agenda preparation, pre-read distribution, travel logistics, and follow-up action item tracking all belong to the medical affairs or clinical team, supported by the EA. The CEO’s time investment in SAB meetings should be productive from the moment they enter the room: briefed on each advisor’s current focus areas, prepared with specific questions, and clear on what decisions the company is trying to get scientific input on.
Between formal meetings, individual SAB members often have insights or availability that could benefit specific programs. A one-hour call with the right key opinion leader at the right moment in a trial design process can save months of internal deliberation. Identifying and executing those moments is part of the CMO’s role, with the CEO participating when the seniority and content warrants direct CEO engagement.
KOL relationships covers the time management principles around key opinion leader engagement in more depth, including how to structure the CEO’s involvement versus delegating to medical affairs.
Academic Medical Center Relationships
Academic medical centers are the primary sites for early-phase combination immunotherapy trials. The principal investigators at these centers are not just investigators; they are scientific collaborators, future publication authors, and in many cases, informal opinion leaders who shape how the oncology community perceives a company’s science.
The CEO’s Role at AMCs
The CEO of an immuno-oncology company should have personal relationships with the principal investigators at their top two or three AMC sites. This does not require frequent contact, but it requires real contact: a direct conversation at ASCO or AACR, an occasional site visit, or a one-on-one call when a significant scientific decision is being made about a trial the investigator is running.
These relationships serve two functions. First, they signal to the investigator community that the CEO takes the science seriously, which affects site engagement and investigator motivation. Second, they give the CEO direct access to clinical feedback about how the combination is performing in early cohorts, unfiltered by internal team interpretation.
The CEO should not be managing AMC relationships at the operational level. Protocol amendments, enrollment discussions, data queries, and site support are all managed by the clinical operations team. The CEO’s role is the high-level scientific relationship, and over-involvement in operational details undermines the clinical team’s authority with site investigators.
Time Allocation for Conference Relationships
ASCO, AACR, ASH (for hematologic malignancies), and ESMO are the primary venues where AMC relationships are maintained and new relationships are built. An immuno-oncology CEO who attends these conferences without a relationship management plan is wasting the attendance. A full conference schedule of back-to-back investor meetings, with no time for substantive scientific interactions, is a misallocation of conference time for an IO CEO.
The EA’s role is to build a structured conference schedule that balances investor obligations, scientific engagement, and key relationship meetings, with sufficient time between meetings for the CEO to be mentally present rather than rushing between commitments.
Managing Combination Trial Complexity: CEO Oversight Without Micromanagement
Combination trials are scientifically and operationally more complex than single-agent studies. They involve more complex eligibility criteria, more demanding safety monitoring requirements, more elaborate biomarker collection protocols, and often more complex response assessment criteria. The trial operations team carries this complexity; the CEO does not.
What the CEO needs to monitor is a small set of leading indicators: enrollment pace against projections, safety monitoring committee activity (any holds or amendments triggered by safety signals), biomarker data quality, and competitive intelligence about similar combinations in development elsewhere.
A monthly one-page program summary from each combination program’s clinical lead, structured around those leading indicators, gives the CEO the oversight information they need without requiring them to attend every trial team meeting. When a summary flags an issue (enrollment below projection, a safety signal under evaluation, a competitor trial reading out), the CEO engages directly. Otherwise, the clinical team manages the work.
Protecting R&D time addresses the broader challenge of maintaining strategic oversight of R&D without allowing operational involvement to crowd out higher-priority CEO work.
Prioritizing Across Programs When Resources Are Constrained
Every immuno-oncology company with multiple combination programs eventually faces resource constraints that require explicit prioritization. Which program gets the additional clinical FTE? Which combination gets the next manufacturing slot? Which partnership gets the CEO’s limited personal attention in a given quarter?
These decisions are the CEO’s to make, and they require enough scientific and operational understanding to make them well. A CEO who does not maintain substantive engagement with their combination portfolio cannot make credible prioritization decisions. The scientific team can provide recommendations, but the final call, which involves commercial timing, partnership dynamics, and investor expectations as well as scientific merit, belongs to the CEO.
According to research published in Nature Reviews Drug Discovery, the success rates for oncology combination therapies depend significantly on rational biomarker-driven patient selection, a strategic decision with CEO-level implications that goes beyond trial design into company positioning.
Building one protected time block per month specifically for cross-program portfolio review, separate from individual program updates, allows the CEO to make these prioritization decisions with full portfolio context rather than in response to whichever team is most vocal in any given week.
Conclusion
Immuno-oncology CEO time management across combination therapy programs requires a structure that is deliberately built and actively maintained. The complexity of the science, the number of external relationships, and the speed at which the field moves create constant pressure to expand the CEO’s operational involvement. That pressure must be resisted.
The most effective IO CEOs are those who invest in the right relationships (pharma partners at the senior level, key AMC investigators, SAB members), maintain portfolio-level oversight through well-designed reporting structures, and delegate operational involvement to capable clinical, regulatory, and partnership management teams. The CEO’s combination therapy time management is ultimately a reflection of how well the entire organization is built to function without constant CEO intervention.
Related Reading
For further context, explore How Biopharma CEOs Manage Time During Merger and Acquisition Due Diligence and How Biosimilar Company CEOs Manage Time Across Development and Market Access.